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ABSTRACT
The aims of this study were to determine whether a multidrug-resistant Acinetobacter baumannii clone,
known to be endemic in three tertiary-care Portuguese hospitals, had disseminated throughout Portugal,
and whether this clone was related to one of the European clones I–III described previously. The isolates
were ﬁrst screened by pulsed-ﬁeld gel electrophoresis and ⁄ or M13 random ampliﬁed polymorphic
DNA ﬁngerprint analysis. Ten representative isolates were compared by ampliﬁed fragment length
polymorphism (AFLP) analysis, and were also compared with isolates contained in the AFLP library of
the Leiden University Medical Centre. All of the Portuguese isolates clustered in European clone II
(clone delineation level >80%). Following AFLP analysis, seven isolates clustered at >96%, indicating a
striking degree of genetic relatedness and suggesting recent spread of a (sub)clone. Three isolates were
slightly more separated from this main group, but all isolates clustered at 87.4%. Thus, the Portuguese
multidrug-resistant isolates formed a sub-cluster of European clone II, suggesting that they belong to a
recent lineage within clone II.
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INTRODUCTION
Bacteria belonging to the species Acinetobacter
baumannii are important opportunistic nosocomial
pathogens that can cause severe infections in
critically-ill patients [1]. These organisms are
notorious for their resistance to antimicrobial
agents [2–6] and their capacity to spread among
hospitalised patients. Comparison of A. baumannii
isolates from different hospitals, cities and coun-
tries using genotypic methods has shown that
multidrug-resistant isolates from different loca-
tions can be very similar, and three major lineages
have been identiﬁed in Europe (named European
clones I–III) [7–10]. These clones can be identiﬁed
by a combination of typing methods, with ampli-
ﬁed fragment length polymorphism (AFLP) ana-
lysis being particularly useful, as its robustness
allows a library of AFLP proﬁles to be established
[8,10,11].
In Portugal, the prevalence of A. baumannii has
been increasing since 1998, especially in intensive
care units of hospitals in different cities. A
previous study using pulsed-ﬁeld gel electro-
phoresis (PFGE) analysis identiﬁed a predomin-
ant multidrug-resistant clone that was endemic in
three tertiary-care hospitals [12], and further data
have indicated that strains belonging to this clone
may have disseminated throughout Portugal dur-
ing recent years (personal unpublished results).
The aims of the present study were to investi-
gate whether these disseminated strains belonged
to the clone described previously [12], and if so,
whether this A. baumannii multidrug-resistant
clone was related genetically to European clones
I–III. Isolates from multiple Portuguese hospitals
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were therefore screened initially for intra- and
inter-hospital similarity by PFGE and ⁄ or random
ampliﬁed polymorphic DNA (RAPD) analysis.
Representative isolates from each hospital were
then compared with each other by AFLP analysis,
and with AFLP proﬁles contained in the library of
the Leiden University Medical Centre, which
includes >1500 AFLP ﬁngerprints of acinetobact-
ers, including strains belonging to European
clones I–III.
MATERIALS AND METHODS
Bacterial isolates
The isolates included in the study were obtained from ten
epidemic episodes in eight hospitals (Table 1), and were
selected on the basis of their multidrug resistance, which
included imipenem resistance. All isolates were identiﬁed as
belonging to the Acinetobacter calcoaceticus–A. baumannii com-
plex by the local hospital laboratories using commercial
identiﬁcation systems. The isolates were sent to the Pharmacy
Faculties of Coimbra and Lisboa and were stored at )80C until
required for further characterisation. In total, 264 isolates were
collected between 1998 and 2004 from different inpatients at
eight hospitals in ﬁve Portuguese cities (Table 1). Of these, 108
isolates from Santa Maria Hospital (HSM) and 23 from the
University Hospitals of Coimbra (HUC) had been characterised
previously by PFGE [12], together with isolates from another
hospital and the SM28 strain from Bilbao, Spain. An additional
133 isolates were recovered between 2000 and 2004 from four
hospitals in Lisboa, i.e., HSM, Sa˜o Francisco Xavier (HSFX), Sa˜o
Jose´ (HSJ) and Santo Anto´nio dos Capuchos (HSAC), and from
other Portuguese cities, namely Setu´bal Hospital (HSB), Caldas
da Rainha Hospital (HCR) and Pombal Hospital (HP) (Table 1).
Antibiotic susceptibility testing
All isolates were tested for their antibiotic susceptibilities at
the participating hospitals using routine automated methods.
Antibiotic susceptibilities were conﬁrmed at FCL by the
standard CLSI (NCCLS) disk-diffusion method [13] with disks
containing amoxycillin, amoxycillin–clavulanic acid, ampicil-
lin–sulbactam, ticarcillin, ticarcillin–clavulanic acid, piperacil-
lin–tazobactam, cefoxitin, cefuroxime, ceftriaxone, cefotaxime,
ceftazidime, cefpirome, cefepime, aztreonam, imipenem,
meropenem, amikacin, gentamicin, tobramycin, nalidixic acid,
ciproﬂoxacin and polymyxin B (Sanoﬁ Pasteur, Lisboa,
Portugal).
Genotypic characterisation and detection of blaOXA-type
enzymes
The genotypic relatedness of isolates collected between 1999
and 2000 was assessed by PFGE as described previously [14].
In brief, chromosomal DNA was digested with ApaI (New
England Biolabs, Izasa, Portugal) and the restriction fragments
were separated by electrophoresis on agarose 1% w ⁄v gels in
0.5 · TBE (1 · TBE is 10 mM Tris-HCl, 1 mM EDTA, pH 8)
buffer at 200 V and 15C for 24 h, with a ramped pulse time of
5–15 s, in a CHEF DRII apparatus (Bio-Rad, Lisboa, Portugal).
Ten representative isolates (Table 1) were subsequently
re-analysed by PFGE with minor modiﬁcations [15]. Chromo-
somal DNA was digested with ApaI and the fragments were
separated by electrophoresis on Seakem Gold agarose 1% w ⁄v
gels with a 19-h run time and a ramped pulse time of 5–20 s at
14C.
RAPD ﬁngerprinting was performed using the core
region of bacteriophage M13 as primer, with the results
interpreted as described by Grundmann et al. [16]. Isolates
showing more than two different bands after electro-
phoresis of the PCR products were considered to be
different strains.
AFLP analysis was performed as described by Nemec et al.
[17]. EcoRI and MseI were used for restriction, and a Cy5-
labelled EcoRI + A primer and MseI + C primer were used for
ampliﬁcation (A and C, selective nucleotides). The ALFexpress
DNA analysis system (Amersham Biosciences, Roosendaal,
The Netherlands) was used for fragment separation. Frag-
ments in the 50–500-bp range were used for cluster analysis
with the BioNumerics v.2.0 software package (Applied Maths,
Sint-Martens-Latem, Belgium), with the Pearson product
moment coefﬁcient (r) as similarity measure and the un-
weighted pair-group average linked method (UPGMA) used
for grouping. For (genomic) species identiﬁcation, isolates
were grouped with reference strains of the known species
contained in the Leiden University Medical Centre AFLP
ﬁngerprint library. Isolates that clustered at a level ‡50% were
considered to belong to the same species [17]. For clonal and
strain identiﬁcation (typing), the proﬁles of isolates were
compared with each other and with proﬁles contained in the
A. baumannii AFLP database of the Leiden University Medical
Centre, which includes numerous proﬁles of strains from
different countries, including strains belonging to European
clones I–III. A grouping level of >90% was used to identify
isolates that belonged to the same strain [17], while a level of
80% was used to delineate major clones [9]. Species identi-
ﬁcation was also performed by ampliﬁed 16S rDNA restriction
analysis. Using this method, restriction proﬁles of the ampli-
ﬁed 16S rDNA sequence generated with ﬁve restriction
enzymes were compared with a library of ampliﬁed 16S
rDNA restriction analysis proﬁles of reference strains [18].
Detection of OXA-type b-lactamases was performed by
PCR as described previously [12].
Table 1. Acinetobacter baumannii isolates recovered from
eight Portuguese hospitals
Hospital, city
No. of
isolates
Period of
occurrence
(month ⁄ year)
Isolates selected
for AFLPa
Santa Maria, Lisboa 108b 10 ⁄ 1998–9 ⁄ 2000 11HSM (LUH9672)
15 10 ⁄ 2004–11 ⁄ 2004 130HSM (LUH9675)
S. Jose´, Lisboa 28 9 ⁄ 2000 12HSJ (LUH9673)
S. F. Xavier, Lisboa 64 2 ⁄ 1999–3 ⁄ 2001 40HSFX (LUH9674)
Dos Capuchos, Lisboa 8 4 ⁄ 2004–10 ⁄ 2004 2HSAC (LUH9671)
De S. Bernardo, Setu´bal 9 2000 4HSB (LUH10687)
University of Coimbra 7b 1 ⁄ 1999–3 ⁄ 1999 142HUC (LUH9676)
16b 11 ⁄ 1999–10 ⁄ 2000 189HUC (LUH10689)
De Caldas da Rainha 3 11 ⁄ 1999 159HCR (LUH9677)
De Pombal 6 2 ⁄ 2004 2396HP (LUH9678)
aDesignations of the Leiden University Medical Centre in parentheses. Isolates were
selected to be representative of the predominant strain at each centre, as based on
M13 random ampliﬁed polymorphic DNA (RAPD) and ⁄ or pulsed-ﬁeld gel
electrophoresis (PFGE) genotyping.
bDescribed in a previous study [12].
AFLP, ampliﬁed fragment length polymorphism.
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RESULTS
Susceptibility tests
The isolates exhibited a similar multidrug resist-
ance pattern, with resistance to amoxycillin and
amoxycillin–clavulanic acid, ampicillin–sulbac-
tam, ureidopenicillins and their combinations,
cefuroxime, cefoxitin, ceftriaxone, cefotaxime,
ceftazidime, cefepime, cefpirome, aztreonam, im-
ipenem, meropenem, quinolones and gentamicin.
However, susceptibility to amikacin, tobramycin
and polymyxin B was variable.
Genotypic characterisation
Isolates from HSM in Lisboa (n = 108) and HUC
(n = 23) (Table 1) had already been typed by
PFGE [12]. For the present study, isolates ob-
tained during 1999–2000 from six other hospitals
were also characterised by PFGE (data not
shown). The isolates differed by three or fewer
PFGE fragments, which indicated a possible
epidemiological relationship according to the
criteria of Tenover et al. [19].
M13 RAPD ﬁngerprinting was used as a
method to rapidly assess genetic relationships
among A. baumannii isolates collected after 2000,
together with representative isolates of each PFGE
pattern established previously. The method
yielded three patterns that were distinguished
by slight variations. A predominant banding
pattern was found in all isolates from all hospi-
tals, and isolates with an identical PFGE pattern
showed the same M13 RAPD ﬁngerprint (data not
shown), providing further evidence for inter-
hospital spread of the same clone over time. The
predominant PFGE banding pattern was the same
as that observed for strain SM28 from Bilbao,
Spain [12], and SM28 also had an M13 RAPD
proﬁle that was indistinguishable from that of the
Portuguese isolates in the present study.
To reduce the number of isolates to be charac-
terised by AFLP, it was assumed that isolates with
highly similar M13 RAPD or PFGE DNA ﬁnger-
prints from a single hospital represented the same
strain. In total, ten isolates from separate outbreak
episodes in the eight institutes were selected for
inter-hospital comparison by AFLP. Fig. 1(a) and
Fig. 1(b) show the genotypic comparison of these
isolates by PFGE and M13 RAPD ﬁngerprinting,
respectively. With PFGE, the ten isolates had a
related but not identical proﬁle, with the isolate in
lane 1, and the isolates in lanes 9 and 10, being
the most distinct. With M13 RAPD ﬁngerprinting,
the isolate in lane 1 differed by three bands, while
the isolates in the other lanes differed, at most, by
one band.
M
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1 Kb
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1 2 3 4 5 6 7 8 9 10 M
Fig. 1. (a) Pulsed-ﬁeld gel electrophoresis (PFGE) ﬁnger-
prints and (b) M13 random ampliﬁed polymorphic DNA
(RAPD) ﬁngerprints of representative Acinetobacter bau-
mannii isolates from eight Portuguese hospitals. Lanes: 1,
2HSAC; 2, 142HUC; 3, 2396HP; 4, 12HSJ; 5, 130HSM; 6,
4HSB; 7, 189HUC; 8, 159HCR; 9, 40HSFX; 10, 11HSM; M,
molecular size marker ((a) lambda ladder; (b) 100-bp
ladder).
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The AFLP proﬁles of all ten isolates clustered at
>50% with those of reference strains of A. bau-
mannii. Similarily, ampliﬁed 16S rDNA restriction
analysis proﬁles were also compatible with iden-
tiﬁcation of the isolates as A. baumannii (CfoI, AluI,
MboI, RsaI, MspI proﬁle: 1 1 1 2 3).
AFLP comparison of the ten selected isolates
also showed that they belonged to European
clone II, as they clustered with clone II isolates at
a level of 84% (Fig. 2). The Portuguese isolates
were in a sub-branch of clone II comprising 18
isolates, including three additional isolates from
the Iberian Peninsula already present in the AFLP
database, all of which linked at 87.4%. Seven
isolates in the present study clustered at a level of
96.7%, indicating a striking degree of genetic
relatedness. Two other isolates, 40HSFX and
11HSM, linked together, while a single isolate,
2HSAC, was slightly more separated. This group-
ing by AFLP agreed well with the results of PFGE
typing, but less so with those of M13 RAPD
ﬁngerprinting, as the latter method was found to
be less discriminatory.
All but one isolate (2396HP ⁄LUH 09678)
yielded an ampliﬁcation product of the expected
size with primers for genes encoding OXA-24-
type b-lactamases.
DISCUSSION
Multidrug-resistant A. baumannii has increasingly
been recognised as being responsible for large
and sustained outbreaks of nosocomial infection.
During a 6-year period, increased numbers of
infections and ⁄ or colonisations associated with
A. baumannii isolates exhibiting a similar, but not
I
II
III 96.3
81.2
84.0
87.4
39 strains
13 strains
5 strains
89.4
96.7
Fig. 2. Dendrogram showing the
relationship of isolates of Acineto-
bacter baumannii from Portuguese
hospitals with strains belonging to
European clone II, but not with
strains belonging to European
clones I and III.
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identical, multiresistant antibiotype were ob-
served in eight hospitals in Portugal. Antibiotic
resistance patterns may be of value in differenti-
ating among strains involved in an outbreak,
especially when a new resistance phenotype
emerges. However, antibiograms should always
be interpreted with caution, since unrelated
strains may exhibit the same antibiogram.
Using PFGE, all Portuguese isolates collected
before 2000, and representative isolates from each
hospital recovered subsequently, were character-
ised by a PFGE pattern showing no more than
three fragment differences. PFGE is considered to
be the standard reference typing method for
many bacteria, and has been shown to be useful
for intra- and inter-laboratory typing of A. bau-
mannii [15]. M13 RAPD ﬁngerprinting is faster
and easier to perform, and can therefore be used
for rapid and easy screening of strains for genetic
relatedness, while PFGE can be used subse-
quently for conﬁrmation. In the present study,
M13 RAPD ﬁngerprinting and PFGE analysis
gave essentially consistent results that conﬁrmed
the geographical spread and persistence of this
clone in Portuguese hospitals. This ﬁnding was
further corroborated by the observation that all
representative isolates, except one, were positive
by PCR for a gene encoding an OXA-24 type
b-lactamase. This gene probably encodes OXA-40,
as this enzyme has been identiﬁed previously by
sequence analysis of isolates from two hospitals
included in the present study [12].
AFLP is a well-established species identiﬁcation
and genomic ﬁngerprinting method that has been
used successfully to study the epidemiology of
A. baumannii [9,11,17]. The AFLP ﬁngerprints of
the Portuguese isolates clustered with isolates
belonging to European clone II (Fig. 2). Seven
isolates formed a cluster that was so closely
related genetically that it seemed to be a recently
disseminated strain. The other three isolates clus-
tered a little separately from this main cluster, but
all the representative isolates investigated were
found to cluster with other Iberian isolates and
isolates from several other countries at a level of
‡87.4%. The Iberian strains were not genetically
identical, but the differences were relatively small.
The 87.4% cluster (Fig. 2) may represent a relat-
ively young subgroup within European clone II.
The isolates in the present study were recov-
ered between 1998 and 2004 from HSM and from
the remaining hospitals between 1999 and 2004,
suggesting transmission among Portuguese hos-
pitals over time. The precise mode of spread is not
known, but patients transfer between district
hospitals and central ⁄university hospitals (HUC
and HSM, located in the centre of the country and
Lisbon, respectively), which may explain the
apparent dissemination. In Portugal, transfer of
patients with serious underlying disease or
trauma from smaller hospital units to larger
well-equipped hospitals is common. Transfer in
the opposite direction also occurs when patients
recover. Despite the infection control measures
taken, these organisms have persisted in the
central hospitals (i.e., HUC and HSM), but con-
sidering the relatively long period of circulation
and the slight variability in the genotype proﬁles
observed for some isolates (especially in HSAC;
see Fig. 1, lane 1, and Fig. 2), the possibility that
some isolates may have evolved independently
from a common ancestor cannot be ruled out.
In conclusion, multidrug-resistant isolates of
A. baumannii in Portuguese hospitals appear to
belong to a sub-cluster of European clone II,
which may represent a recent lineage within clone
II. The capacity to survive in the environment,
together with an enhanced capacity to acquire
antibiotic resistance determinants, may have con-
tributed to the emergence of this sub-cluster. The
frequent occurrence of these organisms in coun-
tries with relatively unrestricted antibiotic poli-
cies is a matter for concern. Further studies are
needed to address the epidemiological and biolo-
gical factors that favour the emergence, dissem-
ination and persistence of these organisms in
European hospitals.
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